POAI - Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | Benzinga
PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.
The abstract highlights results from a recent study that Predictive Oncology completed in collaboration with UPMC Magee-Womens Hospital in Pittsburgh, PA. The study utilized multi-omic machine learning models to determine if they could better predict short- and long-term survival outcomes among women diagnosed with high grade serous ovarian cancer (HGSC) as compared to clinical data alone.
| Title: |
| Using Artificial Intelligence-Powered Evidence-Based Molecular Decision-Making for Improved Outcomes in Ovarian Cancer |
| Abstract #: |
| 5555 |
| Poster bd#: |
| 426 |
| Session: |
| Gynecologic Cancer |
| Date/time: |
| Monday, June 3rd, 9:00am – 12:00pm CDT (10:00am-1:00pm EDT) |